Table 1. Demographics and characteristics.
| Characteristics | Entry completion | 1–20 year survivors (N=5,700) | 20+ year survivors (N=472) | P value |
|---|---|---|---|---|
| Preoperative characteristics | ||||
| Age (years), mean ± SD | 100.0% | 49.6±11.5 | 39.5±10.6 | <0.001 |
| BMI (kg/m2), mean ± SD | 98.9% | 23.5±4.7 | 21.6±4.2 | <0.001 |
| Blood group | ||||
| A | 100.0% | 41.1% | 46.4% | 0.024 |
| B | 10.9% | 15.7% | 0.002 | |
| O | 43.3% | 34.3% | <0.001 | |
| AB | 4.7% | 3.6% | 0.267 | |
| Diagnosis | ||||
| Alpha-1-antitrypsin deficiency | 99.2% | 9.9% | 7.7% | 0.112 |
| COPD/emphysema | 48.6% | 19.2% | <0.001 | |
| Cystic fibrosis | 11.9% | 35.5% | <0.001 | |
| IPF/UIP | 14.4% | 8.7% | <0.001 | |
| Pulmonary hypertension | 4.4% | 8.9% | <0.001 | |
| Male recipient | 100.0% | 48.5% | 46.2% | 0.325 |
| African American recipient | 100.0% | 5.7% | 5.1% | 0.557 |
| Waitlist time (years), mean ± SD | 100.0% | 1.00±0.95 | 1.27±1.04 | <0.001 |
| Donor age (years), mean ± SD | 100.0% | 30.3±12.9 | 28.5±12.3 | 0.003 |
| Male donor | 100.0% | 64.7% | 55.7% | <0.001 |
| African American donor | 100.0% | 13.5% | 9.3% | 0.011 |
| Donor cigarette use | 79.1% | 30.2% | 26.5% | 0.125 |
| Donor creatinine, mean ± SD | 78.8% | 1.21±1.71 | 1.22±2.05 | 0.920 |
| Donor COD | ||||
| Anoxia | 99.4% | 4.1% | 5.8% | 0.081 |
| CVA/stroke | 33.8% | 30.9% | 0.211 | |
| Head trauma | 51.0% | 54.2% | 0.183 | |
| Perioperative characteristics | ||||
| Hospital admission | 99.5% | 4.8% | 4.7% | 0.948 |
| ICU admission | 1.8% | 2.8% | 0.134 | |
| Cold ischemia time (hours), mean ± SD | 90.1% | 4.39±1.73 | 5.20±1.80 | <0.001 |
| Recipient creatinine, mean ± SD | 80.0% | 0.94±1.30 | 0.90±0.91 | 0.490 |
| Life support | 99.5% | 2.8% | 4.1% | 0.104 |
| ABO matching | ||||
| Identical | 100.0% | 91.5% | 92.0% | 0.712 |
| Compatible | 8.5% | 8.1% | 0.741 | |
| Incompatible | 0.1% | 0.0% | 0.618 | |
| Perioperative characteristics | ||||
| HLA mismatch level | ||||
| 0 | 82.0% | 0.0% | 0.0% | 0.678 |
| 1 | 0.5% | 0.8% | 0.497 | |
| 2 | 3.4% | 4.0% | 0.551 | |
| 3 | 12.0% | 13.4% | 0.399 | |
| 4 | 27.6% | 28.4% | 0.733 | |
| 5 | 35.7% | 33.1% | 0.285 | |
| 6 | 20.7% | 20.4% | 0.872 | |
| Gender match (donor to recipient) | ||||
| Male to male | 100.0% | 39.4% | 35.0% | 0.056 |
| Male to female | 25.3% | 20.8% | 0.029 | |
| Female to female | 26.2% | 33.1% | 0.001 | |
| Female to male | 9.1% | 11.2% | 0.129 | |
| Single lung transplant | 100.0% | 63.7% | 23.5% | <0.001 |
| Hospital length of stay (days), mean ± SD | 100.0% | 20.9±26.2 | 22.2±25.9 | 0.584 |
| Post-transplant complications | ||||
| Stroke | 80.2% | 1.6% | 1.5% | 0.884 |
| Dialysis | 80.2% | 1.9% | 3.3% | 0.059 |
| Recipient COD | N=5,282 | N=171 | ||
| Graft failure | 94.1% | 20.8% | 15.2% | 0.074 |
| Pulmonary | 19.2% | 17.5% | 0.593 | |
| Infection | 17.1% | 13.5% | 0.209 | |
| Malignancy | 10.2% | 9.4% | 0.712 | |
| Cardiovascular | 4.9% | 7.0% | 0.201 | |
| Multiple organ failure | 4.2% | 7.0% | 0.069 | |
| Renal failure | 3.3% | 7.0% | 0.007 | |
| Cerebrovascular | 1.6% | 2.3% | 0.444 | |
| Hemorrhage | 1.0% | 0.6% | 0.586 | |
| Non-compliance | 0.4% | 0.0% | 0.409 | |
| Other | 17.4% | 20.5% | 0.295 |
P values <0.05 were considered statistically significant. BMI, body mass index; COPD, chronic obstructive pulmonary disease; IPF/UIP, idiopathic pulmonary fibrosis/usual interstitial pneumonitis; COD, cause of death; CVA, cerebrovascular accident; HLA, human leukocyte antigen.